Azithromycin and lower respiratory tract infections

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 13, 2005, Pages 2335-2351

  Blasi, Francesco ^a   Cazzola, M ^b   Tarsia, P ^a   Cosentini, R ^a   Aliberti, S ^a   Santus, P ^a   Allergra, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

Anti inflammatory effects; Azithromycin; Lower respiratory tract infections

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM; CEFACLOR; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CLARITHROMYCIN; DIRITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; JOSAMYCIN; LEVOFLOXACIN; LINCOSAMIDE DERIVATIVE; LORACARBEF; MACROLIDE; MIKAMYCIN B; MOXIFLOXACIN; PENICILLIN G; PIVAMPICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; TROLEANDOMYCIN; UNINDEXED DRUG;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIINFLAMMATORY ACTIVITY; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG STRUCTURE; HEARING IMPAIRMENT; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMMUNOMODULATION; LIVER DYSFUNCTION; LIVER TOXICITY; LOWER RESPIRATORY TRACT INFECTION; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; QT PROLONGATION; REVIEW; SYSTEMATIC REVIEW; VOMITING;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; AZITHROMYCIN; BRONCHITIS, CHRONIC; CHILD; COMMUNITY-ACQUIRED INFECTIONS; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HAEMOPHILUS INFLUENZAE; HUMANS; MULTICENTER STUDIES; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 27744502221     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.13.2335     Document Type: Review

References (148)

1. BALL P, MAKE B: Acute exacerbations of chronic bronchitis: an international comparison. Chest (1998) 113(Suppl. 3):199S-204S
2. MCGUIRE A, IRWIN DE, FENN P et al.: The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health (2001) 4:370-375.
3. ANTHONISEN NR, MANFREDA J, WARREN CP, HERSHFIELDS ES, HARDING GK, NELSON NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. (1987) 106:196-204.
4. SETHI S: Infectious exacerbations of chronic bronchitis: diagnosis and management. J. Antimicrob. Chemother. (1999) 43(Suppl. A):97-105.
5. BALL P: Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest (1995) 108(Suppl. 2):43S-52S.
6. NIEDERMAN MS, MCCOMBS JS, UNGER AN, KUMAR A, POPOVIAN R: Treatment cost of acute exacerbations of chronic bronchitis. Clin. Ther. (1999) 21:576-591.
7. RATJEN F, DORING G: Cystic fibrosis. Lancet (2003) 361:681-689.
8. SOUTHERN KW, BARKER PM: Azithromycin for cystic fibrosis. Eur. Respir. J. (2004) 24:834-838.
9. MACFARLANE JT, COLVILLE A, GUION A, MACFARLANE RM, ROSE DH: Prospective study of aetiology and outcome of adult lower respiratory-tract infections in the community. Lancet (1993) 341:511-514.
10. JOKINEN C, HEISKANEN L, JUVONEN H et al.: Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am. J. Epidemiol. (1993) 137:977-988.
11. ERS TASK FORCE REPORT: Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Society. Eur. Respir. J. (1998) 11:986-991.
12. NIEDERMAN MS, MANDELL LA, ANZUETO A et al.: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. (2001) 163:1730-1754.
13. VEGELIN AL, BISSUMBHAR P, JOORE JC, LAMMERS JW, HOEPELMAN IM: Guidelines for severe community-acquired pneumonia in the western world. Neth J. Med. (1999) 55:110-117.
14. HEFFELFINGER JD, DOWELL SF, JORGENSEN JH et al.: Management of community acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumonia Therapeutic Working Group. Arch. Intern. Med. (2000) 160:1399-1408.
15. MATSUSHIMA T, JAPANESE RESPIRATORY SOCIETY: The Japanese Respiratory Society Guidelines for management of community-acquired pneumonia in adults. Nippon Rinsho (2003) 61 (Suppl. 2):677-681.
16. MANDELL LA, MARRIE TJ, GROSSMAN RF, CHOW AW, HYLAND RH: Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin. Infect. Dis. (2000) 31:383-421.
17. MANDELL LA, BARTLETT JG, DOWELL SF et al.: Update of practice guidelines for the management of community acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. (2003) 37:1405-1433.
18. BALLOW CH, AMSDEN GW: Azithromycin: the first azalide antibiotic. Ann. Pharmacother. (1992) 26:1253-1261.
19. FINCH RG: Overview of the clinical use of macrolides and streptogramins. In: Expanding Indications for the New Macrolides, Azalides and Streptogramins. SH Zinner, LS Young, FJ Acar, HC Neu (Eds), Marcel Dekker, New York, NY, USA (1997).
20. FIESE EF, STEFFEN SH: Comparison of the acid stability of azithromycin and erythromycin A. J. Antimicrob. Chemother. (1990) 25(Suppl. A):39-47.
21. GLADUE RP, SNIDER ME: Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob. Agents Chemother. (1990) 34:1056-1060.
22. GANDHI R, PILLAI O, THILAGAVATHI R, GOPALAKRISHNAN B, KAUL CL, PANCHAGNULA R: Characterization of azithromycin hydrates. Eur. J. Pharm. Sci. (2002) 16:175-184.
23. PISCITELLI SC, DANZIGER LH, RODVOLD KA: Clarithromycin and azithromycin: new macrolide antibiotics. Clin. Pharm. (1992) 11:137-152.
24. FOULDS G, SHEPARD RM, JOHNSON RB: The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. (1990) 25(Suppl. A):73-82.
25. AMSDEN GW, NAFZIGER AN, FOULDS G: Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrob. Agents Chemother. (1999) 43:163-165.
26. AMSDEN GW, GRAY CL: Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J. Antimicrob. Chemother. (2001) 47:61-66.
27. LUKE DR, FOULDS G, COHEN SF, LEVY B: Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob. Agents Chemother. (1996) 40:2577-2581.
28. AMSDEN GW: Advanced-generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents (2001) 18(Suppl. 1):S11-S15.
29. CAZZOLA M, MATERA MG, TERZANO C, BLASI F, MARSICO SA: Delivering antimicrobials to the lungs: considerations for optimising outcomes. Am. J. Respir. Dis. (2002) 1:261-272.
30. GLADUE RP, BRIGHT GM, ISAACSON RE, NEWBORG MF: In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob. Agents Chemother. (1989) 33:277-282.
31. MEYER AP, BRIL-BAZUIN C, MATTIE H, VAN DEN BROEK PJ: Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus. Antimicrob. Agents Chemother. (1993) 37:2318-2322.
32. JONAS D, ENGELS I, DASCHNER FD, FRANK Y: The effect of azithromycin on intracellular Legionella pneumophila in the Mono Mac 6 cell line at serum concentrations attainable in vivo. J. Antimicrob. Chemother. (2000) 46:385-390.
33. HAND WL, HAND DL: Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int. J. Antimicrob. Agents (2001) 18:419-425.
34. CRAIG WA: Postantibiotic effects and dosing of macrolides, azalides and streptogramins. In: Expanding Indications of the New Macrolides, Azalides and Streptogramins. SH Zinner, LS Young, JF Acar, HC New (Eds), Marcel Dekker, New York, NY, USA (1997):22-38
35. FREEMAN CD, NIGHTINGALE CH, NICOLAU DP, BELLIVEAU PP, BANEVICIUS MA, QUINTILIANI R: Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. Antimicrob. Agents Chemother. (1994) 38:2449-2451.
36. AMSDEN GW, BALLOW CH, FORREST A: Comparison of the plasma, urine and blister fluid pharmacokinetics of clarithromycin and azithromycin in normal subjects. Clin. Drug Invest. (1997) 13:152-161.
37. BALDWIN DR, WISE R, ANDREWS JM, ASHBY JP, HONEYBOURNE D: Azithromycin concentrations at the site of pulmonary infections. Eur. Respir. J. (1990) 3:886-890.
38. BALLOW CH, AMSDEN GW, HIGHET VS, FORREST A: Pharmacokinetics of oral azithromycin in serum, urine, polymorphonuclear leukocytes and inflammatory versus noninflammatory skin blisters. Clin. Drug Invest. (1998) 15:159-167.
39. OLSEN KM, SAN PEDRO GS, GANN LP, GUBBINS PO, HALINSKI DM, CAMPBELL GD Jr: Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob. Agents Chemother. (1996) 40:2852-2855.
40. CONTE JE Jr, GOLDEN J, DUNCAN S, MCKENNA E, LIN E, ZURLINDEN E: Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob. Agents Chemother. (1996) 40:1617-1622.
41. PATEL KB, XUAN D, TESSIER PR, RUSSOMANNO JH, QUINTILIANI R, NIGHTINGALE CH: Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. (1996) 40:2375-2379.
42. CAPITANO B, MATTOES HM, SHORE E et al.: Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest (2004) 125:965-973.
43. RODVOLD KA, DANZIGER LH, GOTFRIED MH: Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob. Agents Chemother. (2003) 47:2450-2457.
44. BAUMANN U, KING M, APP EM, TAI S et al.: Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can. Respir. J. (2004) 11:151-155.
45. BLONDEAU JM, DECAROLIS E, METZLER KL, HANSEN GT: The macrolides. Expert Opin. Investig. Drugs (2002) 11:189-215.
46. HYDE TB, GAY K, STEPHENS DS et al.: Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA (2001) 286:1857-1862.
47. LYNCH JP, MARTINEZ FJ: Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin. Infect. Dis. (2002) 34(Suppl. 1):S27-S46.
48. HALPERN MT, SCHMIER JK, SNYDER LM et al.: Meta-analysis of bacterial resistance to macrolides. J. Antimicrob. Chemother. (2005) 55:748-757.
49. CARBON C, POOLE MD: The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J. Chemother. (1999) 11:107-118.
50. ARASON VA, KRISTINSSON KG, SIGURDSSON JA, STEFANS-DOTTIR G, MOLSTAD S, GUDMUNDSSON S: Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. Br. Med. J. (1996) 313:387-391.
51. AMSDEN GW: Pneumococcal macrolide resistance - myth or reality? J. Antimicrob. Chemother. (1999) 44:1-6.
52. JACKSON MA, BURRY VF, OLSON LC, DUTHIE SE, KEARNS GL: Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr. Infect. Dis. J. (1996) 15:1049-1051.
53. FOGARTY C, GOLDSCHMIDT R, BUSH K: Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin. Infect. Dis. (2000) 31:613-615.
54. KELLEY MA, WEBER DJ, GILLIGAN P, COHEN MS: Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin. Infect. Dis. (2000) 31:1008-1011.
55. WATERER GW, WUNDERINK RG, JONES CB: Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest (2000) 118:1839-1840.
56. MUSHER DM, DOWELL ME, SHORTRIDGE VD et al.: Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N. Engl. J. Med. (2002) 346:630-631.
57. LONKS JR, GARAU J, GOMEZ L, XERCAVINS M, DE ECHAGÜEN AO, GAREEN IF et al.: Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. (2002) 35:556-564.
58. EWIG S, RUIZ M, TORRES A et al.: Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am. J. Respir. Crit. Care Med. (1999) 159:1835-1842.
59. DAGAN R, LEBOVITZ E, GREENBERG D et al.: Dynamics of pneumococcal nasopharyngeal colonization during the first days of antibiotic treatment in pediatric patients. Ped. Infect. Dis. J. (1998) 17:880-885.
60. BALMES P, CLERC G, DUPONT B, LABRAM C, PARIENTE R, POIRIER R: Comparative study of azitrhomycin and amoxycillin/clavulanic acid in the treatment of lower respiratory tract infections. Eur. J. Clin. Microbiol. Infect. Dis. (1991)10(5):437-439.
61. MERTENS JC, VAN BARNEVELD PW, ASIN HR, LIGTVOET E, VISSER MR, BRANGER T et al.: Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. Antimicrob. Agents Chemother. (1992) 36:1456-1459.
62. BRADBURY F: Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. J. Antimicrob. Chemother. (1993) 31(Suppl. E):153-162.
63. DARK D: Azithromycin versus cefaclor in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Curr. Therap. Res. Clin. Exp. (1993) 53:203-211.
64. SEVIERI G, ROGGI G, MONACCI A: A comparison between amoxycillin clavulanic acid and azithromycin in exacerbations of chronic bronchitis sustained by Haemophilus influenzae. Minerva Pneumologica (1993) 32(2):67-70.
65. HOEPELMAN AI, SIPSA AP, VAN HELMOND JL et al.: A single-blind comparison of three-day azithromycin and 10-day co-amoxiclav treatment of acute lower respiratory tract infections. J. Antimicrob. Chemother. (1993) 31 (Suppl. E): 147-152.
66. MORANDINI G, PERDUCA M, TANNINI G, FASCHINO MP, MIRAGLIOTTA G, CARNIMEO NS: Clinical efficacy of azithromycin in lower respiratory tract infections. J. Chemother. (1993) 5:32-36.
67. POZZI E, GROSSI E, PECORI A: Azithromycin versus clarithromycin in the treatment of acute exacerbations of chronic bronchitis. Curr. Therap. Res. Clin. Exp. (1994) 55:759-764.
68. BARSIC B, SCHONWALD S, KLINAR I, SAGUD M, SUSKOVIC T: Comparison of three-day azithromycin and ten-day cefaclor in the treatment of patients with bacterial lower respiratory tract infection. Pharmaca (1994) 32:137-146.
69. WHITLOCK W: Multicenter comparison of azithromycin and amoxicillin/clavulanate in the treatment of patients with acute exacerbations of chronic obstructive pulmonary disease. Curr. Therap. Res. Clin. Exp. (1995) 56:985-995.
70. BEGHI G, BERNI F, CARRATU L et al.: Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbations of chronic bronchitis. J. Chemother. (1995) 7:146-152.
71. BIEBUYCK XA, FOR THE AZITHROMYCIN STUDY GROUP: Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. J. Int. Med. Res. (1996) 24:407-418.
72. ZACHARIAH J: A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of Azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections. J. Antimicrob. Chemother. (1996) 37(Suppl.):103-113.
73. GRIS P: Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. J. Antimicrob. Chemother. (1996) 37(Suppl. C):93-101.
74. LAURENT K: Efficay, safety and tollerability of azithromycin versus roxihtromycin in the treatment of acute lower respiratory tract infections. J. Antimicrob. Chemother. (1996) 37(Suppl. C):115-124.
75. HOEPELMAN IM, MOLLERS MJ, VAN SCHIE MH et al.: A short (3- day) course of azithromycin tablets versus a 10-day course of amoxicillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int. J. Antimicrob. Agents (1998) 9:141-146.
76. SOEPANDI P, MANNGUNNEGORO H, YUNUS F, GUNAWAN J: The pattern of micro-organisms and the efficacy of new macrolides in acute lower respiratory tract infections. Respirology (1998) 3:113-117.
77. CAZZOLA M, VINCIGUERRA A, DIPERNA F et al.: Comparative study of dirithromycin and azithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis. J. Chemother. (1999) 11:119-125.
78. DEABATE CA, MATHEW CP, WARNER JH, HEYD A, CHURCH D: The safety and efficay of short course (5-day) moxifloxacin versus azitrhromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Respir. Med. (2000)94:1029-1037.
79. SCHOUENBORG P, GERDES N, RASMUSSEN HH et al.: Azithromycin versus pivampicillin in the treatment of acute exacerbations of chronic bronchitis. J. Int. Med. Res. (2000) 28:101-110.
80. CASTALDO RS, CELLI BR, GOMEZ F et al.: A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin. Ther. (2003) 25:542-557.
81. AMSDEN GW, BAIRD IM, SIMON S, TREADWAY G: Efficacy and safety of azithromycin versus levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest (2003) 123 (3):772-777.
82. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (1995) 152:S77-S120.
83. PANPANICH R, LERTTRAKARNNON P, LAOPAIBOON M: Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst. Rev. (2004) 4:CD001954.
84. CONTOPOULOS-IOANNIDIS DG, IOANNIDIS JP, CHEW P, LAU J: Metaanalysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J. Antimicrob. Chemother. (2001) 48:691-703.
85. DAVIES G, WILSON R: Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax (2004) 59:540-541.
86. GERHARDT SG, MCDYER JF, GIRGIS RE et al.: Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am. J. Respir. Crit. Care Med. (2003) 168:121-125.
87. RAHAV G, FIDEL J, GIBOR Y, SHAPIRO M: Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. Int. J. Antmicrob. Agents (2004) 24:181-184.
88. LENTINO JR, KRASNICKA B: Association between initial empirical therapy and decreased length of stay among veteran patients hospitalized with community-acquired pneumonia. Int. J. Antimicrob. Agents (2002) 19:61-66.
89. FELDMAN RB, RHEW DC, WONG JY, CHARLES RA, GOETZ MB: Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. (2003) 163:1718-1726.
90. PLOUFFE J, SCHWARTZ DB, KOLOKATHIS A et al.: Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia: the Azithromycin Intravenous Clinical Trials Group. Antimicrob. Agents Chemother. (2000) 44:1796-1802.
91. VERGIS EN, INDORF A, FILE TM Jr et al.: Azithromycin versus cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trail. Arch. Intern. Med. (2000) 160:1294-1300.
92. STAHL JE, BARZA MD, DESFARDIN J et al.: Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. (1999) 159:2576-2580.
93. MARTINEZ JA, HORCAJADA JP, ALMELA M et al.: Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. (2003) 36:389-395.
94. GLEASON PP, MEEHAN TP, FINE JM et al.: Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med. (1999) 159:2562-2572.
95. BROWN RB, IANNINI P, GROSS P et al.: Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest (2003) 123:1503-1511.
96. TROWBRIDGE JF, ARTYMOWICZ RJ, LEE CE et al.: Antimicrobial selection and length of hospital stay in patients with community-acquired pneumonia. J. Clin. Outcomes Management (2002) 9:613-619.
97. SÁNCHEZ F, MENSA J, MARTÍNEZ JA et al.: Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? Clin. Infect. Dis. (2003) 36:1239-1245.
98. ZERVOS M, MANDELL LA, VROOMAN PS et al.: Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat. Respir. Med. (2004) 3:329-336.
99. SCHÖNWALD S, KUZMAN I, ORESKOVIC K et al.: Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome-a randomized study. Infection (1999) 27:198-202.
100. ROORD JJ, WOLF BH, GOSSENS MM et al.: Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. Antimicrob. Agents Chemother. (1996) 40:2765-2768.
101. HARRIS JA, KOLOKATHIS A, CAMPBELL M, CASSELL GH, HAMMERSCHLAG MR: Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr. Infect. Dis. J. (1998) 17:865-871.
102. WUBBEL L, MUNIZ L, AHMED A et al.: Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr. Infect. Dis. J. (1999) 18:98-104.
103. RUUSKANEN O: Safety and tolerability of azithromycin in pediatric infectious diseases: 2003 update. Pediatr Infect Dis (2004) 23:S135-S139.
104. POWERS JL: Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. Pediatr. Infect. Dis. J. (1996) 15:S30-S37.
105. BALTER MS, LA FORGE J, LOW DE, MANDELL L, GROSSMAN RF: on behalf of the Canadian Thoracic Society and the Canadian Infectious Disease Society: Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can. Respir. J. (2003) 10(Suppl. B):3B-32B.
106. MACFARLANE J: Severe pneumonia and a second antibiotic. Lancet (2002) 359:1170-1172.
107. KAUPPINEN M, SAIKKU P: Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Clin. Infect. Dis. (1995) 21:5244-5252.
108. LIEBERMAN D, BEN-YAAKOV M, LAZAROVICH Z et al.: Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients. Infection (1996) 24:109-114.
109. HOWE RA, SPENCER RC: Macrolides for the treatment of Pseudomonas aeruginosa infections? J. Antimicrob. Chemother. (1997) 40:153-155.
110. MIZUKANE R, HIRAKATA Y, KAKU M et al.: Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1994) 38:528-533.
111. ICHIMIYA T, TAKEOKA K, HIRAMATSU K, HIRAI K, YAMASAKI T, NASU M: The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy (1996) 42:186-191.
112. COSTERTON JW, STEWART PS, GREENBERG EP: Bacterial biofilms: a common cause of persistent infections. Science (1999) 284:1318-1322.
113. GEISENBERGER O, GIVSKOV M, RIEDEL K, HOIBY N, TUMMLER B, EBERL L: Production of N-acyl-L-homoserine lactones by P. aeruginosa isolates from chronic lung infections associated with cystic fibrosis. FEMS Microbiol. Lett. (2000) 184:273-278.
114. TATEDA K, COMTE R, PECHERE JC, KOHLER T, YAMAGUCHI K, VAN DELDEN C: Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (2001) 45(6):1930-1933.
115. IMAMURA Y, YANAGIHARA K, MIZUTA Y et al.: Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-oxododecanoyl) homoserine lactone in NCI-H292 Cells. Antimicrob. Agents Chemother. (2004) 48:3457-3461.
116. NGUYEN T, LOUIE SG, BERINGER PM et al.: Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. Curr. Opin. Pulm. Med. (2002) 8:521-528.
117. MOLINARI G, GUZMAN CA, PESCE A et al.: Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J. Antimicrob. Chemother. (1993) 31:681-688.
118. VRANES J: Effect of subminimal inhibitory concentrations of azithromycin on adherence of Pseudomonas aeruginosa to polystyrene. J. Chemother. (2000) 12:280-285.
119. WOLTER J, SEENEY S, BELL S, BOWLER S, MASEL P, MCCORMACK J: Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax (2002) 57:212-216.
120. EQUI A, BALFOUR-LYNN IM, BUSH A, ROSENTHAL M: Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet (2002) 360:978-984.
121. SAIMAN L, MARSHALL BC, MAYER-HAMBLETT N et al.: Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA (2003) 290:1749-1756.
122. SOUTHERN KW, BARKER PM, SOLIS A: Macrolide antibiotics for cystic fibrosis (Cochrane Rev). In: The Cochrane Library (Issue no. 3) John Wiley and Sons Ltd, Chichester, UK (2004).
123. CIPOLLI M, CAZZOLA G, NOVELLI A, CASSETTA MI, FALLIANI S, MAZZEI T: Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis. Clin. Drug Invest. (2001) 21:353-360.
124. RIPOLL L, REINERT P, PEPIN LF, LAGRANGE PH: Interaction of macrolides with alpha dornase during DNA hydrolysis. J. Antimicrob. Chemother. (1996) 37:987-991.
125. IMAMURA Y, HIGASHIYAMA Y, TOMONO K et al.: Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob. Agents Chemother. (2005) 49:1377-1380.
126. LABRO MT: Anti-inflammatory activity of macrolides: a new therapeutic potential? J. Antimicrob. Chemother (1998) 41(Suppl. B):37-46.
127. CAZZOLA M, MATERA MG, BLASI F: Macrolide and occult infection in asthma. Curr. Opin. Pulm. Med. (2004) 10:7-14.
128. GAREY KW, ALWANI A, DANZIGER LH, RUBINSTEIN I: Tissue reparative effects of macrolicle antibiotics in chronic inflammatory sinopulmonary diseases. Chest (2003) 123:261-265.
129. Spector SL, Katz FH, Farr RS: Troleandomycin: effectiveness in steroid-dependent asthma and bronchitis. J Allergy Clin. Immunol. (1974) 54:267-279.
130. LAFORCE CF, SZEFLER SJ, MILLER ME et al.: Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J. Allergy Clin. Immunol. (1983) 72:34-39.
131. VON ROSENSTEIL NA, ADAM D: Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf. (1995)13:105-122.
132. EKICI A, EKICI M, ERDEMOGLU AK: Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma. J. Asthma (2002) 39:181-185.
133. SCAGLIONE F, ROSSONT G: Comparative anti-inflammatory effects of roxithromycin, azithromycin, and clarithromycin. J. Antimicrob. Chemother. (1998) 41:47-50.
134. SCHULTZ MJ: Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J. Antimicrob. Chemother. (2004) 54:21-28.
135. RUBIN B: Immunomodulatory properties of macrolides: overview and historical perspective. Am. J. Med. (2004) 117:2S-4S
136. SHIMIZU T, SHIMIZU S, HATTORI R, GABAZZA EC, MAJIMA Y: In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am. J. Respir. Crit. Care Med. (2003) 168:581-587.
137. KUDOH, S, AZUMA, A, YAMAMOTO M, IZUMI T, ANDO M: Improvement of survival in patients with diffuse panbronchiolitis treated with low dose erythromycin. Am. J. Respir. Crit. Care Med. (1998) 157:1829-1832.
138. KUDOH S: Erythromycin treatment in diffuse panbronchiolitis. Curr. Opin. Pulm. Med. (1998) 4:116-121.
139. CULIC, O, ERAKOVIC V, CEPELAK I et al.: Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur. J. Pharmacol. (2002) 450:277-289.
140. AMSDEN GW: Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother. (2005) 55(1):10-21
141. GUAY DR: Pharmacokinetics of new macrolides. Infect. Med. (1992) 9:31-38.
142. NAHATA M: Drug interactions with azithromycin and the macrolides: an overview. J. Antimicrob. Chemother. (1996) 37(Suppl. C):133-142.
143. HOPKINS S: Clinical toleration and safety of azithromycin in adults and children. Rev. Contem. Pharmacother. (1994) 5:383-389.
144. PERITI P, MAZZEI T, MINI E, NOVELLI A: Adverse effects of macrolide antibacterials. Drug Saf. (1993) 9(5):346-364.
145. STRLE F, MARASPIN V: Is azithromycin treatment associated with prolongation of the Q-Tc interval? Wien Klin Wochenschr (2003) 114:396-399.
146. PRINCIPI N, ESPOSITO S: Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf. (1999) 20(1):25-41.
147. TREADWAY G, REISMAN A: Tolerability of 3-day, once-daily azithromycin suspension versus standard treatments for community-acquired paediatric infectious diseases. Int. J. Antimicrob. Agents (2001) 18:427-431.
148. SETHI S, ANZUETO A, FARRELL DJ: Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis. Ann. Clin. Microbiol. Antimicrob. (2005) 4(1):5.